Novartis Boosts its Oncology Position
Taskin Ahmed
Abstract
Novartis has acquired the rights to two investigational drugs from Incyte Corp indicated for myelofibrosis, blood disorders and cancer in a deal that could exceed US$1 B.
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.